Assessing clinical complete response after neoadjuvant systemic therapy in muscle-invasive bladder cancer: a systematic review

评估肌层浸润性膀胱癌新辅助全身治疗后的临床完全缓解:一项系统评价

阅读:2

Abstract

PURPOSE: Reliable assessment of clinical complete response (cCR) is essential to facilitate bladder-sparing treatment approaches in patients with muscle-invasive bladder cancer (MIBC) undergoing neoadjuvant systemic therapy, yet there is no agreement on the choice of diagnostic modalities for its assessment. We aimed to summarize strategies for assessing cCR in MIBC to facilitate development of bladder-preservation strategies. METHODS: In this prospectively registered systematic review (CRD420251088678), we searched MEDLINE, Embase, and Web of Science in July 2025 for studies reporting on cCR in MIBC patients undergoing neoadjuvant therapy prior to definitive local therapy or bladder preservation strategies. Risk-of-bias (RoB) was assessed using ROBINS-I tool. RESULTS: Out of 1696 individual records, 41 studies comprising 3588 patients were included in this systematic review. Majority of studies used cisplatin-based neoadjuvant therapies (n = 2941, 23 studies), with eight studies including perioperative immunotherapy (n = 647). For cCR evaluation, 12 studies (n = 1064) used only medical imaging (including CT, MRI, or FDG-PET/CT), three studies (n = 231) performed re-TURBT, one study (n = 56) used cystoscopy, and the remaining 25 studies (n = 2237) assessed cCR through combinations of medical imaging and clinical evaluation. Reported cCR rates ranged from 4.2% to 45% for CT, 15% to 78% for MRI, 76% for FDG-PET/CT, 25% to 46% for TURBT, 50% for cystoscopy, and 7.4% to 87% in studies combining medical imaging with local clinical evaluation. Most studies were rated as having moderate RoB concerns, while one preliminary report was classified as having serious RoB due to limited sample size. CONCLUSION: We found substantial heterogeneity in cCR assessment modalities, limiting comparability across bladder-sparing studies and highlighting the need for standardization. Data on patients receiving neoadjuvant chemo-immunotherapy remain scarce, and none incorporated urinary tumor DNA in cCR definitions. Serial MRI, with or without invasive assessment, appears promising for selecting candidates for bladder preservation. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00345-025-06146-7.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。